Larvol Delta - IL2-With-Ipilimumab-Followed-by-Nivolumab-in-Stage-3-or-4-Melanoma-Patients

Yervoy (ipilimumab) - BMS

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

Proleukin (aldesleukin) - Iovance Biotherap

http://clinicaltrials.gov/ct2/show/NCT04562129

Sep 3, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next